Logo

American Heart Association

  2
  0


Final ID: MDP944

Predictors of Developing Ischemia-Reperfusion Injury Immediately after Heart Transplantation

Abstract Body (Do not enter title and authors here): Introduction: Post-heart Transplant (HTx) ischemia-reperfusion injury (IRI) is not uncommon and has been associated with an increased risk of rejection and cardiac allograft vasculopathy. IRI may occur due to long ischemia time, high dose inotropes, and technical surgical reasons. Identifying other recipient and donor characteristics that might set patients at higher risk for developing IRI might help inform decision-making and improve patient outcomes. Therefore, we aim to investigate predictors of developing IRI immediately after HTx.
Methods: Between 2010 and 2020, we assessed 893 patients undergoing HTx at our center. Recipient and donor characteristics were collected and compared between patients who were noted to have immediate post-HTx (within 30 days) IRI on their endomyocardial biopsy (n=241) vs. those who did not (n=652). Multivariable logistic regression was used to determine predictors of IRI development and included all univariate significant variables with (P<0.1). Outcomes were represented as odds ratios with corresponding 95% confidence intervals.
Results: Among 893 patients undergoing HTx, 241 (27%) had IRI within 30 days post-HTx (time to IRI was 14.4 ± 7.3 days). Compared to patients without IRI, those who developed IRI trended towards being older (57 ± 12 vs. 55 ±13 years, P=0.07), were less likely to receive induction therapy with anti-thymocyte globulin (ATG) (43.6 vs. 52.9%, P=0.01), and less likely to be listed with an urgent status at the time of HTx (62.7% vs. 71.9%, P=0.008). Patients listed with an urgent status were on optimal hemodynamic support. No other significant differences were recorded in other pre-transplant or peri-operative recipient characteristics among patients who developed IRI vs. those who did not. In regard to donor characteristics, those who developed IRI received hearts from older donors (37 ± 13.5 vs. 34.9 ± 12.2, P=0.03) and showed a trend toward a higher likelihood of donor-recipient sex mismatch (29.9% vs. 23.6%, P=0.059), regardless of recipient sex. On multivariable logistic regression, only ATG-induction [OR:0.69, 95%CI [0.51-0.93], P=0.015) therapy and urgent status at transplantation [OR:07, 95%CI [0.51-0.96], P=0.028) were significant predictors of IRI development
Conclusion: Optimal prioritization of HTx candidates on the waitlist and use of ATG induction therapy seem to protect against immediate IRI post-HTx.
  • Manla, Yosef  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Patel, Jignesh  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Kittleson, Michelle  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Nikolova, Andriana  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Chang, David  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Kransdorf, Evan  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Stern, Lily  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Czer, Lawrence  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Kobashigawa, Jon  ( Cedars-Sinai Smidt Heart Institute , Los Angeles , California , United States )
  • Author Disclosures:
    Yosef Manla: DO NOT have relevant financial relationships | Jignesh Patel: No Answer | Michelle Kittleson: DO NOT have relevant financial relationships | Andriana Nikolova: No Answer | David Chang: DO have relevant financial relationships ; Individual Stocks/Stock Options:ABBV:Active (exists now) ; Research Funding (PI or named investigator):Biokardia:Active (exists now) ; Research Funding (PI or named investigator):Mesoblast:Past (completed) ; Research Funding (PI or named investigator):Amgen:Past (completed) ; Individual Stocks/Stock Options:Repligen:Active (exists now) ; Individual Stocks/Stock Options:Amarin:Active (exists now) ; Individual Stocks/Stock Options:Abbot:Active (exists now) | Evan Kransdorf: DO NOT have relevant financial relationships | Lily Stern: DO NOT have relevant financial relationships | Lawrence Czer: DO have relevant financial relationships ; Research Funding (PI or named investigator):Impulse Dynamics:Active (exists now) | Jon Kobashigawa: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Updates in Heart Transplant

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
CLEC4E Signaling in Myocardial Ischemia-Reperfusion Injury

Algoet Michiel, Pusovnik Matic, Caluwe Ellen, Gillijns Hilde, Gsell Willy, Himmelreich Uwe, Oosterlinck Wouter, Janssens Stefan

Analysis of 30-Day Readmission Rates and Costs Post-Heart Transplant: A 12-Year Retrospective Study Using Nationwide Readmission Database(NRD) : 2010-2021

Pinninty Dheeraj, Mogga Phanidhar, Raol Karanrajsinh, Pillai Ashwin, Mudduluru Prathyusha, Singh Kerry, Jedeon Zeina, Jaiswal Abhishek

More abstracts from these authors:
Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?

Manla Yosef, Kobashigawa Jon, Patel Jignesh, Kittleson Michelle, Kanungo Avani, Nikolova Andriana, Kransdorf Evan, Chang David, Czer Lawrence, Stern Lily

Five-year Outcomes of Heart-Kidney Transplant Recipients Bridged with Durable Mechanical Circulatory Support: Less AMR Better Survival?

Manla Yosef, Kobashigawa Jon, Patel Jignesh, Kittleson Michelle, Nikolova Andriana, Chang David, Kransdorf Evan, Stern Lily, Czer Lawrence, Lee Mason

You have to be authorized to contact abstract author. Please, Login
Not Available